Skip to main content

Table 3 (abstract O17). Migraine disability assessment total score, month 6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  LFEM HFEM  
Treatment Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb p-valuec
Placebo 25.7 (22.6) 241 -9.8 ± 1.4    36.9 (31.5) 483 -15.1 ± 1.2    
Galca 120mg 25.1 (21.8) 126 -18.6 ± 1.8 -8.8 ± 1.9 <.001 35.3 (30.2) 254 -22.3 ± 1.5 -7.2 ± 1.5 <.001 .557
Galca 240mg 28.7 (24.6) 124 -15.9 ± 1.8 -6.2 ± 1.9 .001 37.2 (29.7) 241 -22.1 ± 1.5 -7.0 ± 1.6 <.001 .737
  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; bp-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo